Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT04118855 trial: what clinicians have said so far
Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
- NCT04118855 ↗
- Completed
- RenJi Hospital
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT04118855 (toripalimab plus axitinib in locally advanced nonmetastatic clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04118855 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Phase II Study of Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Neoadjuvant Therapy of Non-metastatic Locally Advanced Renal Cell Carcinoma
- Interventions
- Toripalimab; Axitinib
- Arms
- Neoadjuvant arm · Experimental
- Enrollment
- 20
- Primary outcomes
- Objective Tumor Response Rate
- Sponsor
- RenJi Hospital
- Start
- Mar 1, 2020
- Primary completion
- Feb 28, 2023
- Results posted
- No
- Registry record
- NCT04118855 · updated Apr 4, 2023
Publications
linked from the registry- Huang J, Wang Y, Xu F, Wang Z, Wu G, Kong W, Cheoklong NG, Tricard T, Wu X, Zhai W, Zhang W, Zhang J, Zhang D, Chen S, Lian Y, Chen Y, Zhang J, Huang Y, Xue W. Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial. J Immunother Cancer. 2024 Jun 11;12(6):e008475. doi: 10.1136/jitc-2023-008475. PubMed 38862251